European Medicines Agency: multiple sclerosis medicine Zinbryta will be voluntarily withdrawn from the market

Medicine to be voluntarily withdrawn from the market by the company LONDON, 06-Mar-2018 — /EuropaWire/ — The European Medicines Agency (EMA) has started an urgent review of the multiple sclerosis medicine Zinbryta (daclizumab) following 7 cases of serious inflammatory brain disorders … Read the full press release →